Pyelonephritis is a bacterial infection of the kidneys that can lead to serious complications if left untreated. The annual prevalence in the United States is approximately 15 to 17 cases per 10,000 females and 3 to 4 cases per 10,000 males. There is a significant unmet clinical need for improved therapies, as current treatment options, mainly antibiotics, face challenges such as drug resistance and suboptimal efficacy in severe cases. The growing focus on innovative drug development, including targeted therapies and advanced diagnostics, is expected to support pipeline growth. These advancements aim to enhance treatment outcomes and address the limitations of current therapeutic options.
The Pyelonephritis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into pyelonephritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pyelonephritis. The pyelonephritis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pyelonephritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pyelonephritis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pyelonephritis.
Pyelonephritis is a kidney infection primarily caused by bacteria ascending from the urinary tract. It occurs when bacteria, commonly Escherichia coli, enter the kidneys, leading to inflammation and possible scarring. The disease can be acute or chronic and is more common in women. The drug pipeline is focused on novel antibiotics, immunotherapies, and vaccines to address antibiotic resistance and improve treatment outcomes.
Pyelonephritis treatment generally involves antibiotics to combat the bacterial infection. In severe cases, intravenous antibiotics or hospitalization may be required. For recurrent infections, long-term antibiotic prophylaxis may be prescribed. Future treatments in the pipeline include targeted therapies and vaccines aimed at preventing infections and reducing antibiotic resistance.
The pyelonephritis drug pipeline targets infections primarily caused by bacteria that ascend from the bladder. Epidemiological data indicates that the prevalence in the United States is 15 to 17 cases per 10,000 females and 3 to 4 per 10,000 males, with an increasing incidence in men over 55 years. In Japan, urinary tract infection hospitalizations occur at 6.8 per 10,000 men and 12.4 per 10,000 women. Pyelonephritis often develops from untreated or severe urinary tract infections.
This section of the report covers the analysis of pyelonephritis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total pyelonephritis clinical trials.
The drug molecule categories covered under the pyelonephritis pipeline analysis include small molecules, gene therapy, biologics, and peptides. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pyelonephritis.
The EMR report for the pyelonephritis report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is a list of a few players involved in pyelonephritis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pyelonephritis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pyelonephritis drug candidates.
Sponsored by Spero Therapeutics, the Phase 3 PIVOT-PO study aims to assess the efficacy of oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) compared to intravenous Imipenem-cilastatin in participants with complicated urinary tract infections (cUTI) or acute pyelonephritis (AP). The study, with an estimated 2,648 participants, is expected to be completed by November 2025. The primary objective is to evaluate the overall response at the Test-of-Cure (TOC) visit.
A Phase 2 study sponsored by Rempex, a subsidiary of Melinta Therapeutics, evaluates the safety, tolerability, and pharmacokinetics of Meropenem-Vaborbactam in children with complicated urinary tract infections, including acute pyelonephritis. The study, expected to be completed by July 2027, aims to enroll 66 participants. The primary objective is to assess the drug's safety and tolerability in this population.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Pyelonephritis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for pyelonephritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within pyelonephritis pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share